Profile data is unavailable for this security.
About the company
Genix Pharmaceuticals Corporation is a life-sciences company. The Company is a formulator, manufacturer, licensor and marketer of life sciences related products with a focus on nutraceuticals and pharmaceuticals. The Company is focused on the research, development, manufacturing, licensing and selling of novel and healthcare products. These products include evidence-based, proprietary over the counter (OTC) nutraceuticals, and other single molecule generic drugs. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid soft gels, seal oil soft gels, marine lipid soft gels, Lecithin soft gels, fish oil soft gels, EPO soft gels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and Artificial Tearssingle-molecule.
- Revenue in CAD (TTM)3.98k
- Net income in CAD-4.00m
- Incorporated1998
- Employees--
- LocationGenix Pharmaceuticals CorpSuite 300, 1055 West Hastings StVANCOUVER V6E 2E9CanadaCAN
- Phone+1 (604) 609-6198
- Fax+1 (604) 710-9461
- Websitehttps://genixpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aequus Pharmaceuticals Inc | 278.21k | -2.86m | 1.99m | 12.00 | -- | -- | -- | 7.15 | -0.0216 | -0.0216 | 0.0021 | -0.0423 | 0.2937 | 1.34 | 4.26 | -- | -302.43 | -97.96 | -- | -293.31 | 53.31 | -- | -1,029.67 | -141.53 | 0.0431 | -13.68 | 10.65 | -- | -81.53 | -28.97 | 7.64 | -- | -- | -- |
Genix Pharmaceuticals Corp | 3.98k | -4.00m | 2.37m | -- | -- | -- | -- | 595.22 | -0.0675 | -0.0675 | 0.00007 | -0.023 | 0.002 | 0.0104 | 0.444 | -- | -196.19 | -54.69 | -661.13 | -68.59 | 57.79 | -- | -100,442.00 | -5,345.88 | 0.0412 | -3.29 | -- | -- | -- | -50.60 | -309.27 | -- | -- | -- |
Radient Technologies Inc | 3.15m | -11.30m | 2.65m | 33.00 | -- | -- | -- | 0.8418 | -0.0216 | -0.0216 | 0.006 | -0.0278 | 0.1108 | 1.56 | 6.00 | -- | -39.76 | -67.36 | -- | -118.27 | -3.91 | 1.66 | -359.00 | -534.11 | 0.0251 | -3.58 | -- | -- | 45.49 | 65.30 | 69.41 | -- | 200.33 | -- |
Intellipharmaceutics International Inc | 1.22m | -4.28m | 2.66m | 33.00 | -- | -- | -- | 2.18 | -0.1293 | -0.1293 | 0.0369 | -0.5246 | 0.6027 | -- | 3.37 | -- | -211.39 | -132.15 | -- | -- | -88.96 | -- | -350.72 | -499.37 | -- | -19.36 | -- | -- | -- | -58.75 | 43.78 | -- | -- | -- |
Manitex Capital Inc. | 0.00 | 676.04k | 2.83m | -- | 4.22 | 0.335 | 5.13 | -- | 0.0534 | 0.0534 | 0.00 | 0.6716 | 0.00 | -- | -- | -- | 7.45 | -10.84 | 8.10 | -11.51 | -- | -- | -- | -- | -- | -- | 0.0392 | -- | -- | -- | 103.54 | 17.10 | -- | -- |